|
1
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bramer JA, van Linge JH, Grimer RJ and
Scholten RJ: Prognostic factors in localized extremity
osteosarcoma: A systematic review. Eur J Surg Oncol. 35:1030–1036.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou W, Hao M, Du X, Chen K, Wang G and
Yang J: Advances in targeted therapy for osteosarcoma. Discov Med.
17:301–307. 2014.PubMed/NCBI
|
|
6
|
Tan ML, Choong PF and Dass CR:
Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol
Ther. 8:106–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun K and Lai EC: Adult-specific functions
of animal microRNAs. Nat Rev Genet. 14:535–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Behm-Ansmant I, Rehwinkel J and Izaurralde
E: MicroRNAs silence gene expression by repressing protein
expression and/or by promoting mRNA decay. Cold Spring Harb Symp
Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai Y, Yu X, Hu S and Yu J: A brief review
on the mechanisms of miRNA regulation. Genomics Proteomics
Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bracken CP, Scott HS and Goodall GJ: A
network-biology perspective of microRNA function and dysfunction in
cancer. Nat Rev Genet. 17:719–732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin W, Zhu X, Yang S, Chen X, Wang L,
Huang Z, Ding Y, Huang L and Lv C: MicroRNA-203 inhibits
proliferation and invasion, and promotes apoptosis of osteosarcoma
cells by targeting Runt-related transcription factor 2. Biomed
Pharmacother. 91:1075–1084. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang Z, Jiang C, Yu C and Fang J:
MicroRNA-208b inhibits human osteosarcoma progression by targeting
ROR2. Tumour Biol. 39:10104283177057512017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu X, Yan L, Liu Y, Xian W, Wang L and
Ding X: MicroRNA-448 suppresses osteosarcoma cell proliferation and
invasion through targeting EPHA7. PLoS One. 12:e01755532017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tian L, Guo Z, Wang H and Liu X:
MicroRNA-635 inhibits the malignancy of osteosarcoma by inducing
apoptosis. Mol Med Rep. 16:4829–4834. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim YH, Goh TS, Lee CS, Oh SO, Kim JI,
Jeung SH and Pak K: Prognostic value of microRNAs in osteosarcoma:
A meta-analysis. Oncotarget. 8:8726–8737. 2017.PubMed/NCBI
|
|
18
|
Kushlinskii NE, Fridman MV and Braga EA:
Molecular mechanisms and microRNAs in osteosarcoma pathogenesis.
Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Q, Li S, Wu Y and Gao F: miRNA-708
functions as a tumour suppressor in hepatocellular carcinoma by
targeting SMAD3. Oncol Lett. 14:2552–2558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Galun D, Basaric D, Zuvela M, Bulajic P,
Bogdanovic A, Bidzic N and Milicevic M: Hepatocellular carcinoma:
From clinical practice to evidence-based treatment protocols. World
J Hepatol. 7:2274–2291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Zhong X, Pan X and Ji Y: Tumor
suppressive microRNA-708 targets Notch1 to suppress cell
proliferation and invasion in gastric cancer. Oncol Res. 2018.
|
|
23
|
Song XF, Wang QH and Huo R: Effects of
microRNA-708 on epithelial-mesenchymal transition, cell
proliferation and apoptosis in melanoma cells by targeting LEF1
through the Wnt signaling pathway. Pathol Oncol Res. 25:377–389.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim EA, Kim SW, Nam J, Sung EG, Song IH,
Kim JY, Kwon TK and Lee TJ: Inhibition of c-FLIPL expression by
miRNA-708 increases the sensitivity of renal cancer cells to
anti-cancer drugs. Oncotarget. 7:31832–31846. 2016.PubMed/NCBI
|
|
25
|
Delsin LEA, Roberto GM, Fedatto PF, Engel
EE, Scrideli CA, Tone LG and Brassesco MS: Downregulated
adhesion-associated microRNAs as prognostic predictors in childhood
osteosarcoma. Pathol Oncol Res. 25:11–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu D, Zhang C, Li X, Zhang H, Pang Q and
Wan A: MicroRNA-567 inhibits cell proliferation, migration and
invasion by targeting FGF5 in osteosarcoma. EXCLI J. 17:102–112.
2018.PubMed/NCBI
|
|
28
|
Du L, Chen T, Zhao K and Yang D: miR-30a
suppresses osteosarcoma proliferation and metastasis by
downregulating MEF2D expression. Onco Targets Ther. 11:2195–2202.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao Q, Pei Y, Zhang X and Xie B:
microRNA-96 acts as a tumor suppressor gene in human osteosarcoma
via target regulation of EZRIN. Life Sci. 203:1–11. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo P, Lan J, Ge J, Nie Q, Mao Q and Qiu
Y: miR-708 acts as a tumor suppressor in human glioblastoma cells.
Oncol Rep. 30:870–876. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lei SL, Zhao H, Yao HL, Chen Y, Lei ZD,
Liu KJ and Yang Q: Regulatory roles of microRNA-708 and microRNA-31
in proliferation, apoptosis and invasion of colorectal cancer
cells. Oncol Lett. 8:1768–1774. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H,
Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, et al:
Increased miR-708 expression in NSCLC and its association with poor
survival in lung adenocarcinoma from never smokers. Clin Cancer
Res. 18:3658–3667. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song T, Zhang X, Zhang L, Dong J, Cai W,
Gao J and Hong B: miR-708 promotes the development of bladder
carcinoma via direct repression of Caspase-2. J Cancer Res Clin
Oncol. 139:1189–1198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Li H, Cao R, Sun L, Wang Y, Fan
S, Zhao Y, Kong D, Cui L, Lin L, et al: Suppression of miR-708
inhibits the Wnt/β-catenin signaling pathway by activating DKK3 in
adult B-all. Oncotarget. 8:64114–64128. 2017.PubMed/NCBI
|
|
35
|
Zhou YM, Cao L, Li B, Zhang RX, Sui CJ,
Yin ZF and Yang JM: Clinicopathological significance of ZEB1
protein in patients with hepatocellular carcinoma. Ann Surg Oncol.
19:1700–1706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y, Liu G, Wu S, Jiang F, Xie J and
Wang Y: Zinc finger E-box-binding homeobox 1: Its clinical
significance and functional role in human thyroid cancer. Onco
Targets Ther. 9:1303–1310. 2016.PubMed/NCBI
|
|
37
|
Li J, Xia L, Zhou Z, Zuo Z, Xu C, Song H
and Cai J: MiR-186-5p upregulation inhibits proliferation,
metastasis and epithelial-to-mesenchymal transition of colorectal
cancer cell by targeting ZEB1. Arch Biochem Biophys. 640:53–60.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Larsen JE, Nathan V, Osborne JK, Farrow
RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, et
al: ZEB1 drives epithelial-to-mesenchymal transition in lung
cancer. J Clin Invest. 126:3219–3235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jia B, Liu H, Kong Q and Li B:
Overexpression of ZEB1 associated with metastasis and invasion in
patients with gastric carcinoma. Mol Cell Biochem. 366:223–229.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shen A, Zhang Y, Yang H, Xu R and Huang G:
Overexpression of ZEB1 relates to metastasis and invasion in
osteosarcoma. J Surg Oncol. 105:830–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu C and Lin J: Long noncoding RNA
ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically
activating ZEB1. Am J Transl Res. 8:4095–4105. 2016.PubMed/NCBI
|
|
42
|
Xu J, Wang Z, Liao Z, Dai D and Ma X:
MicroRNA-150 functions as an antioncogenic regulator in
osteosarcoma. Oncol Lett. 14:2483–2490. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yan H, Zhang B, Fang C and Chen L: miR-340
alleviates chemoresistance of osteosarcoma cells by targeting ZEB1.
Anticancer Drugs. 29:440–448. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang H, Xing D, Ren D, Feng W, Chen Y,
Zhao Z, Xiao Z and Peng Z: MicroRNA643 regulates the expression of
ZEB1 and inhibits tumorigenesis in osteosarcoma. Mol Med Rep.
16:5157–5164. 2017. View Article : Google Scholar : PubMed/NCBI
|
